Cosmetic and Reconstructive Surgery Market is Huge, Cytori Therapeutics (NASDAQ: CYTX)
November 17th, 2009
No comments
Updating our Cytori Therapeutics blogs of 11/3/09 and 11/10/09 … Completion of the RESTORE 2 study is – IMPORTANT – because it lays the foundation for – reimbursement – in the EU; CYTX is already – CE Marked – for certain uses in the EU!
- Breast cancer is the most frequent cancer in women worldwide; it is responsible for 26.5% of all new cancer cases and 17.5% of EU cancer deaths among women. In the enlarged EU, there are around 270,000 new cases of breast cancer each year and 96,000 cancer deaths. Breast cancer prevalence is rising in the EU due to increasing age and shows no signs of stopping,
- Interim data on the first 32 patients who have reached the 6 month follow-up will be presented as a “poster” at the San Antonio Breast Cancer Symposium on 12/12/09.
